tetano
Editor, Senior Moderator
Pathogens
. 2020 Nov 5;9(11):E917.
doi: 10.3390/pathogens9110917.
Antibody-Based Immunotherapeutic Strategies for COVID-19
Jamal Hussen[SUP] 1 [/SUP], Mahmoud Kandeel[SUP] 2 3 [/SUP], Maged Gomaa Hemida[SUP] 1 4 [/SUP], Abdullah I A Al-Mubarak[SUP] 1 [/SUP]
Affiliations
Abstract
Global efforts to contain the coronavirus disease-2019 (COVID-19) include the development of novel preventive vaccines and effective therapeutics. Passive antibody therapies using convalescent plasma, SARS-CoV-2 (Severe-Acute-Respiratory-Syndrome-Corona-Virus-2)-specific neutralizing antibodies (NAbs), and the development of monoclonal antibodies (MAbs) are among the most promising strategies for prophylaxis and treatment of SARS-CoV-2 infections. In addition, several immunomodulatory antibodies acting via several mechanisms to boost the host immune defense against SARS-CoV-2 infection as well as to avoid the harmful overreaction of the immune system are currently under clinical trial. Our main objective is to present the current most up-to-date progress in some clinical trials registered at ClinicalTrials.gov. We highlight the pros and pitfalls of several SARS-CoV-2 antibody-based immunotherapeutics.
Keywords: COVID-19; SARS CoV-2; antibodies; clinical trials; immunotherapy.
. 2020 Nov 5;9(11):E917.
doi: 10.3390/pathogens9110917.
Antibody-Based Immunotherapeutic Strategies for COVID-19
Jamal Hussen[SUP] 1 [/SUP], Mahmoud Kandeel[SUP] 2 3 [/SUP], Maged Gomaa Hemida[SUP] 1 4 [/SUP], Abdullah I A Al-Mubarak[SUP] 1 [/SUP]
Affiliations
- PMID: 33167401
- DOI: 10.3390/pathogens9110917
Abstract
Global efforts to contain the coronavirus disease-2019 (COVID-19) include the development of novel preventive vaccines and effective therapeutics. Passive antibody therapies using convalescent plasma, SARS-CoV-2 (Severe-Acute-Respiratory-Syndrome-Corona-Virus-2)-specific neutralizing antibodies (NAbs), and the development of monoclonal antibodies (MAbs) are among the most promising strategies for prophylaxis and treatment of SARS-CoV-2 infections. In addition, several immunomodulatory antibodies acting via several mechanisms to boost the host immune defense against SARS-CoV-2 infection as well as to avoid the harmful overreaction of the immune system are currently under clinical trial. Our main objective is to present the current most up-to-date progress in some clinical trials registered at ClinicalTrials.gov. We highlight the pros and pitfalls of several SARS-CoV-2 antibody-based immunotherapeutics.
Keywords: COVID-19; SARS CoV-2; antibodies; clinical trials; immunotherapy.